206A PRISM BioLab Co.,LTD - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

206A

TSE Growth

PRISM BioLab Co.,LTD

277

JPY

-14

(-4.81%)

Dec 23, 3:30 pm JST

1.76

USD

Dec 23, 1:30 am EST

Result

ー

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep, 2021 ＊	58	ー	-153	-155	-7.8	0	ー	J-GAAP
Sep, 2022 ＊	554	66	78	72	2.7	0	ー	J-GAAP
Sep, 2023 ＊	112	-496	-497	-526	-19.1	0	ー	J-GAAP
Sep, 2024	305	-782	-831	-1,049	-33.5	0	Nov 14, 2024	J-GAAP
Sep, 2025 Guidance	ー	ー	ー	ー	－	0	Nov 14, 2024	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Sep, 2024	Jul 2, 2024	300	-888	-914	-1,160	0*	J-GAAP
Results	Nov 14, 2024	305	-782	-831	-1,049	0*	J-GAAP
Sep, 2025	Nov 14, 2024	ー	ー	ー	ー	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Sep, 2019	106	－	Available in future release
Sep, 2020	206	+94.3
Sep, 2021	58	-71.8
Sep, 2022	554	+855.2
Sep, 2023	112	-79.8
Sep, 2024	305	+172.3
Sep, 2025 Guidance	ー	-100.0	ー	+100.0	ー	+100.0	－	+100.0

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Sep, 2023 ＊	112	-496	-443	-37.29	-35.65	0.08	-19.1
Sep, 2024	305	-782	-256	-45.13	-36.56	0.11	-33.5
Sep, 2025 Guidance	ー	ー	ー	ー	ー	ー	－

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	554	66	78	72	2.7
Fiscal Year	Sep, 2022	Sep, 2022	Sep, 2022	Sep, 2022	Sep, 2022

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	115	-334	-322	-336	-11.6	0	ー	J-GAAP
Oct - Mar, 2024 Guidance	ー	ー	ー	ー	－	0	Nov 14, 2024	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Sep, 2022	66	95	102	-7	110	1,687	96.95	J-GAAP
Sep, 2023	-496	-553	-513	-40	ー	1,133	93.56	J-GAAP
Sep, 2024	-782	-94	150	-244	3,370	4,392	97.00	J-GAAP

Actual Performance and Financial Trends

Historical Performance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep, 2022	554	66	78	72	2.7	0	ー	J-GAAP
Sep, 2023	112	-496	-497	-526	-19.1	0	ー	J-GAAP
Sep, 2024	305	-782	-831	-1,049	-33.5	0	Nov 14, 2024	J-GAAP
YoY	+172.3%	-57.7%	-67.2%	-99.4%	-75.6%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	42	-148	-149	-153	-5.6	-352.4	ー	J-GAAP
Jan - Mar, 2024	73	-186	-173	-183	-6.3	-254.8	ー	J-GAAP
Apr - Jun, 2024	100	-209	-174	-233	-7.8	-209.0	Aug 14, 2024	J-GAAP
Jul - Sep, 2024	90	-239	-335	-480	-15.3	-265.6	Nov 14, 2024	J-GAAP
YoY	－	－	－	－	－

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2023	42	－	Available in future release
Jan - Mar, 2024	73	－
Apr - Jun, 2024	100	－
Jul - Sep, 2024	90	－	-239	－	-335	－	-15.3	－

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	100	-148	-149	-153	-5.6
Fiscal Year	Jun, 2024	Dec, 2023	Dec, 2023	Dec, 2023	Dec, 2023

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Sep, 2022	-3,082.00	96.2	1,740	1,674	ー	ー	ー	J-GAAP
Sep, 2023	-6,900.00	94.7	1,211	1,147	-493	ー	ー	J-GAAP
Sep, 2024	97.41	77.3	4,528	3,502	-1,542	ー	Nov 14, 2024	J-GAAP

PRISM BioLab Co.,LTD(206A) Financial Results